Trends in ICHRA adoption, product innovation, and regulatory developments signal that this benefits model isn’t just here to stay — it’s poised to help redefine how we think about employer-sponsored healthcare. The post 2025 Outlook: Significant Investments in ICHRA Signal Changes Ahead appeared first on MedCity News.
Roche will share in developing and commercializing petrelintide, a clinical-stage Zealand Pharma drug that activates the amylin receptor to spark weight loss. This agreement represents the highest total financial consideration in the obesity field to date. The post Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity appeared first on…
Intercept Pharmaceuticals is voluntarily withdrawing from the market Ocaliva, a drug for the rare liver disease primary biliary cholangitis. While Ocaliva became an important new treatment option when it won accelerated FDA approval in 2016, PBC patients now have new FDA-approved medicines from Ipsen and Gilead Sciences that don’t pose the same safety risks. The…
President Donald Trump’s return to the White House sent a clear signal about Medicaid to Republicans across the country: Requiring enrollees to prove they are working, volunteering, or going to school is back on the table. The day after Trump’s inauguration, South Carolina GOP Gov. Henry McMaster asked federal officials to approve a work requirement…
[Sponsored] Mayo Clinic Platform_Solutions Studio is designed to help digital health companies to accelerate the development and deployment of their technologies. The post Mayo Clinic Platform Helps Digital Health Startups Soar by Resolving Innovation Challenges appeared first on MedCity News.
Sociologist Elena Portacolone was taken aback. Many of the older adults in San Francisco she visited at home for a research project were confused when she came to the door. They’d forgotten the appointment or couldn’t remember speaking to her. It seemed clear they had some type of cognitive impairment. Yet they were living alone….
A growing body of evidence shows that structured lifestyle interventions such as physical activity, nutrition, and stress management aren’t just helpful; they also reduce cancer recurrence, improve quality of life, lower mortality, and even decrease healthcare costs. The post It’s Time to Make Lifestyle Interventions Standard in Oncology appeared first on MedCity News.
Acquisition builds on Ascend’s recent additions of myTIPreport and Clover Learning
Transcarent is planning to acquire Accolade for $621 million, the companies announced Wednesday. The two companies are very complementary and the deal gives Accolade a chance to turn things around after struggling in the public market, experts say. The post Accolade Gets a Do-Over With Transcarent’s $621M Acquisition appeared first on MedCity News.
That is the title of a new USC white paper by Darren Filson, Karen Van Nuys, Darius Lakdawalla and Dana Goldman with the subtitle “How Much Does Revenue Drive New Drug Development?” What is the elasticity of innovation? It measures the percentage change in innovation—using the flow of new drugs approvals, or Phase 1, 2,…